Consensus estimates project a Q2 2026 loss of $0.31 per share on revenue of $7.45 million, while the current stock price of $5.81 reflects a significant discount to the average analyst price target of $26.41. Investors are primarily focused on regulatory feedback from the FDA regarding a potential accelerated approval pathway for WVE-006, the company's first-in-class RNA editing candidate for alpha-1 antitrypsin deficiency.
Following Wave’s recent move to regain full global rights for WVE-006 from GSK, the market is highly sensitive to clinical execution and platform validation. Simultaneously, shareholders are watching for updates on the Phase 2a INLIGHT trial for WVE-007, an obesity treatment that previously demonstrated compelling body composition data.